HLS Therapeutics Inc experienced a notable uptick in its stock price this week, despite a broader trend of decline over the past month.
HLS Therapeutics Inc (HLS.TO) saw its stock rise by 3.92% in the last trading session, closing at C$3.87. However, the stock has experienced a decline of 3.40% this week and is down 17.94% year-to-date. This price action comes amid mixed financial results and new product launches, which have not yet translated into sustained investor confidence.
Investor takeaway: While HLS Therapeutics has shown recent growth in specific product sales, overall investor sentiment remains cautious due to declining stock performance and negative profit margins. The recent announcements of financial results and share buybacks may provide some support, but the market appears to be weighing these factors carefully.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeAdvertisement
Market cap
$119.78M
52W high
$5.76
52W low
$3.81
1W change
-3.40%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 81.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.21
+81.3% Upside
Current Price
C$3.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
29.7%
Annualized
90-Day Vol
24.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.75 | C$3.38 – C$4.16 |
| 60 trading days | C$3.53 | C$3.06 – C$4.09 |
| 90 trading days | C$3.33 | C$2.79 – C$3.98 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
C$3.87 closing price, with a 3.92% increase on the day.
The stock's volume surged to 287,990 shares, significantly above the 20-day average of 6,361 shares, indicating heightened trading activity and potential investor interest.
Bull case
The company reported a 15% increase in net sales for Vascepa and launched NILEMDO™ in Canada, which could drive future revenue growth. Additionally, the Normal Course Issuer Bid aims to reduce share supply, potentially supporting the stock price.
Bear case
Despite recent revenue growth, HLS Therapeutics continues to operate at a loss, with a profit margin of -18.5% and a return on equity of -16.4%. The stock's underperformance against moving averages and high volume compared to the 20-day average suggests ongoing investor caution.
Recent Price Action
Advertisement
HLS Therapeutics Inc saw its stock price close at C$3.87, reflecting a 3.92% increase in the last trading day. However, the stock has declined by 3.40% over the past week and has fallen 17.94% year-to-date. This price movement occurs against a backdrop of mixed financial performance and new product launches.
Company News
While there were no major announcements this week, recent headlines indicate that HLS Therapeutics reported Q1 2026 revenue of $12.9 million, up 2% year-over-year, and highlighted a 15% growth in Vascepa net sales. Additionally, the company announced a Normal Course Issuer Bid to repurchase up to 1,500,000 common shares over the next year, which may be aimed at supporting the stock price.
Technical Picture
HLS Therapeutics' stock is currently trading below both its 50-day moving average of C$4.27 and its 200-day moving average of C$4.61, indicating a bearish trend. The 52-week range for the stock is C$3.81 to C$5.76, with the current price at approximately 3% of this range. The stock's beta of 0.86 suggests lower volatility compared to the broader market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
